Molecular Partners Engages with Investors
Molecular Partners AG (NASDAQ: MOLN), a dynamic biotech firm, is set to increase its visibility and engagement with the investment community in the upcoming months. The Company, known for its unique DARPin therapeutics, will participate in various investor conferences where key executives will share insights and updates.
Participation in Key Conferences
At the forefront, Molecular Partners will engage in fireside chats at both the TD Cowen 44th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. These platforms provide a pivotal opportunity for the Company to outline its strategies and convey its current research developments.
TD Cowen 44th Annual Health Care Conference
The conference is scheduled for the first week of March, running from the 3rd to the 5th. Molecular Partners CEO Patrick Amstutz and CMO Dr. Philippe Legenne will lead discussions during a fireside chat on March 3 at 9.10 am ET. Participants can expect an in-depth dialogue focused on the company’s vision and future.
Leerink Partners Global Healthcare Conference
Following the Cowen event, Molecular Partners will present at the Leerink Partners Global Healthcare Conference in Miami, scheduled for March 10-12. The same executive team will host a fireside chat on March 10, allowing for further exploration of the Company’s innovative approaches in biotech.
Discussion of Financial Results
On another crucial front, Molecular Partners will host a conference call on March 7 to discuss its financial results for the full year of 2024. This call will be an essential occasion for stakeholders and the public to gain insight into the Company’s financial health and future outlook.
Financial Results Conference Call Details
The call will commence at 8.00 am ET (2.00 pm CET). Interested parties should dial in approximately ten minutes prior to the start of the presentation. For easy access, here are the registration numbers:
Toll-Free Dial-In: 1-844-763-8274
International Dial-In: 1-412-717-9224
Switzerland Dial-In: 044-575-0267
Molecular Partners' Innovative Approach
Founded in 2004, Molecular Partners AG is pioneering the design of DARPin therapeutics, which offer targeted solutions for medical challenges that existing drugs sometimes fail to address. The firm primarily focuses on oncology, leveraging its unique DARPin technology to provide meaningful advancements in patient care.
Future Directions and Collaborations
The Company continues to expand its research initiatives while strategically collaborating with leading pharmaceutical firms to enhance its developmental pipeline. This focus on partnerships not only strengthens its capabilities but also maximizes the potential for breakthrough treatments.
Company Overview and Contact Information
Molecular Partners has headquarters in both Zurich, Switzerland and Concord, Massachusetts, USA, reflecting its commitment to both European and North American markets. For further details about the innovative work being done at Molecular Partners AG, you can visit their official website at www.molecularpartners.com, where updates and additional company information are readily available.
Contact Details
For further inquiries, stakeholders may contact:
Seth Lewis, SVP Investor Relations & Strategy
Email: seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Email: laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Frequently Asked Questions
What is Molecular Partners AG known for?
Molecular Partners AG specializes in developing DARPin therapeutics, focusing primarily on oncology.
When will the financial results for 2024 be announced?
The financial results will be discussed in a conference call scheduled for March 7, 2025.
Where will the investor conferences take place?
Molecular Partners will participate in the TD Cowen Conference in Boston and the Leerink Partners Conference in Miami.
Who are the key speakers at the upcoming conferences?
Molecular Partners CEO Patrick Amstutz and CMO Dr. Philippe Legenne will be the primary speakers.
How can investors contact Molecular Partners for inquiries?
Investors can reach out to Seth Lewis or Laura Jeanbart via email for any inquiries regarding the Company.
